Head-to-head comparisons of medication uses, side effects, warnings, and more.
Gilenya (fingolimod) and Aubagio (teriflunomide) are both oral medications used to treat relapsing forms of multiple sclerosis (MS), but they work in different ways. Gilenya is a sphingosine 1-phosphate receptor modulator that lowers the number of white blood cells to reduce nerve damage, while Aubagio is a pyrimidine synthesis inhibitor that calms the immune system by blocking a specific enzyme. Gilenya can be used in both adults and children aged 10 and older, whereas Aubagio is only for adults. Gilenya requires close monitoring for heart issues, especially during the first dose, and can cause serious side effects like infections and liver problems. Aubagio also has serious risks, including liver damage and severe skin reactions, and it can stay in your body for up to two years after stopping. Both medications are not safe during pregnancy and require birth control use. Gilenya is available in two forms: a capsule and an orally disintegrating tablet, while Aubagio is only available as a tablet.
Fingolimod (Gilenya) is a disease-modifying treatment option for relapsing multiple sclerosis (MS). It works well to lower the number of MS relapses. Fingolimod (Gilenya) is taken by mouth, typically once daily, and can be used by adults and children age 10 years and older. But fingolimod (Gilenya) can cause potentially serious side effects, such as a higher risk for infections and heart problems, so it's not the best choice for everyone.
Teriflunomide (Aubagio) helps treat relapsing forms of multiple sclerosis (MS) in adults. It's a type of disease-modifying therapy (DMT) that helps slow down MS and lower the number of relapses. The typical dose is 1 tablet by mouth once a day. Side effects includes headache, diarrhea, and hair loss. Teriflunomide (Aubagio) comes as a brand-name and generic medication.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.